Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Organisation › Details

Proclara Biosciences Inc.

Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer’s disease. *


Period Start 2016-09-01 renamed
  Predecessor NeuroPhage Pharmaceuticals Inc.
Products Industry Alzheimer drug
  Industry 2 therapeutic protein
Person Person Bruhn, Suzanne (Proclara 201802 CEO)
Region Region Cambridge, MA
  Country United States (USA)
  Street 85 Bolton Street
  City 02140 Cambridge, MA
  Tel +1-617-941-7020
    Address record changed: 2018-07-07
Basic data Employees n. a.
    * Document for �About Section�: Proclara Biosciences, Inc.. (9/7/16). "Press Release: Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease". Cambridge, MA.
Record changed: 2019-07-13


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Proclara Biosciences Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top